Global Rnai Technologies - 2025 -2033
RNAi Technology Market Size and Growth
The global RNAi technology market size reached US$ 2.75 Billion in 2024 from US$ 2.51 Billion in 2023 and is expected to reach US$ 6.63 Billion by 2033, growing at a CAGR of 10.4% during the forecast period 2025-2033. The market is expanding rapidly, driven by the clinical success of approved siRNA drugs, advances in delivery systems like GalNAc conjugates and lipid nanoparticles, and rising investments from pharma and biotech partnerships. North America currently dominates revenues, but Asia-Pacific is poised for the fastest growth due to increasing R&D and manufacturing capacity. The market outlook is strong, particularly in rare diseases, oncology, and metabolic disorders, though challenges in extra-hepatic delivery and high development costs remain key hurdles.
Key Market Trends & Insights
Drivers-Proven clinical validation with first-to-market RNAi therapeutics is significantly driving the RNAi technology market growth
The proven clinical validation of first-to-market RNAi therapeutics is one of the most powerful catalysts driving the RNAi technology market’s growth. For years, RNAi was viewed largely as a promising research tool, but skepticism persisted around its clinical viability due to delivery and safety challenges. This changed with the approval of Onpattro (patisiran) in 2018, the first siRNA-based drug approved for treating hereditary transthyretin-mediated amyloidosis. Its success not only validated RNAi’s therapeutic potential but also demonstrated that gene silencing could translate into meaningful patient outcomes.
This milestone was quickly followed by other approvals, such as Givlaari (givosiran) for acute hepatic porphyria, Oxlumo (lumasiran) for primary hyperoxaluria, and Leqvio (inclisiran) for hypercholesterolemia, collectively establishing RNAi as a credible therapeutic modality. Each approval has progressively built trust among regulators, investors, and pharmaceutical companies, reducing uncertainties around safety, durability, and regulatory pathways.
These successes have proven RNAi’s scalability beyond ultra-rare diseases, with inclisiran marking a significant step into the large cardiovascular market. The commercial performance of these drugs, combined with positive Phase III trial results from emerging candidates, has attracted major partnerships and licensing deals between RNAi-focused biotechs like Alnylam and Arrowhead and global pharma leaders. This validation loop successful approvals driving partnerships, funding, and expanded pipelines, is significantly accelerating the overall RNAi market, transforming it from a niche innovation into a mainstream therapeutic platform.
Restraints-Regulatory complexity and evolving safety concerns are hampering the growth of the RNAi technology market
The growth of the RNAi technology market is hampered by ongoing regulatory complexity and evolving safety concerns, which create hurdles for both developers and investors. Despite several successful approvals, regulatory agencies like the FDA and EMA continue to scrutinize RNAi drugs closely due to risks such as off-target gene silencing, immune activation, and hepatotoxicity. Since RNAi therapies often involve repeat dosing for chronic diseases, regulators demand long-term safety data, which prolongs clinical timelines and increases costs. Manufacturing complexities, particularly in ensuring consistent quality of chemically modified oligonucleotides, add another layer of regulatory oversight.
Moreover, uncertainties remain around how RNAi therapies will be evaluated against competing modalities like CRISPR or antisense oligonucleotides, leading to inconsistencies in trial design expectations. These regulatory bottlenecks, combined with the lingering perception of RNAi as a “new” modality, slow down approvals and can dampen investor confidence when unexpected safety issues arise in clinical trials. As a result, while regulatory acceptance of RNAi has improved, the high bar for safety and evolving guidelines remain significant restraints to faster market growth.
Market Segment Analysis
The RNAi technology market is segmented based on product type, therapeutic application, end-user, and region.
Product Type-The siRNA (small interfering RNA) segment is dominating the RNAi technology market with a 43.61% share in 2024
The siRNA (small interfering RNA) segment is dominating the RNAi technology market because it has delivered the most successful and clinically validated products to date, establishing itself as the core therapeutic modality in RNAi. siRNAs are synthetic double-stranded oligonucleotides that precisely silence disease-causing genes, and their design flexibility, combined with advances in delivery technologies such as GalNAc conjugates and lipid nanoparticles, has made them commercially viable.
The landmark approval of Onpattro (patisiran) in 2018 for hereditary transthyretin-mediated amyloidosis was the first breakthrough, proving siRNA’s potential in rare genetic diseases. This was followed by other Alnylam products like Givlaari (givosiran) for acute hepatic porphyria, Oxlumo (lumasiran) for primary hyperoxaluria, and Amvuttra (vutrisiran), which further validated siRNA’s role in treating liver-related disorders. Additionally, Leqvio (inclisiran), co-developed by Novartis and Alnylam, marked a major expansion of siRNA into the cardiovascular market, addressing high cholesterol in a much larger patient population. These successes demonstrate siRNA’s scalability beyond ultra-rare diseases, making it the most commercially advanced RNAi segment.
Market Geographical Share
North America is expected to dominate the RNAi technology market with a 44.13% in 2024
North America holds dominance in the RNAi technology market due to its advanced biotech ecosystem, strong funding landscape, and early regulatory approvals of pioneering RNAi drugs. The US, in particular, is home to industry leaders such as Alnylam Pharmaceuticals, which has successfully commercialized multiple siRNA therapies, including Onpattro (patisiran), Givlaari (givosiran), and Oxlumo (lumasiran), setting global benchmarks for RNAi therapeutics. The region also spearheaded the launch of Leqvio (inclisiran) in collaboration with Novartis, marking a major expansion into the high-prevalence cardiovascular disease space.
North America benefits from supportive regulatory frameworks, with the FDA granting designations like orphan drug and breakthrough therapy that have accelerated development timelines for RNAi assets. Additionally, strong academic institutions and research centers in the US and Canada drive innovation in RNAi delivery systems and preclinical research. The presence of established pharmaceutical companies actively partnering with RNAi-focused biotechs further strengthens commercialization pathways. These factors, combined with a high prevalence of genetic and metabolic disorders, robust reimbursement infrastructure, and significant venture capital interest, ensure that North America continues to lead in both revenue share and pipeline advancement in the RNAi technology market.
Market Companies and Competitive Landscape
Top companies in the RNAi technology market include Alnylam Pharmaceuticals, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Creative Biolabs, GenScript, Revvity, Promega Corporation, OriGene Technologies, Inc. and Altogen Biosystems, among others.
Alnylam Pharmaceuticals, Inc.: Alnylam Pharmaceuticals, Inc. is the undisputed leader in the RNAi technology market, having pioneered the first FDA-approved siRNA drug, Onpattro (patisiran), and subsequently expanding its portfolio with Givlaari, Oxlumo, and Amvuttra. The company has established a stronghold in rare genetic and hepatic disorders while also expanding into broader areas like cardiovascular disease through partnerships, such as with Novartis for Leqvio (inclisiran). With a robust pipeline, proprietary delivery platforms, and strategic collaborations, Alnylam continues to set industry benchmarks, driving both innovation and commercialization in RNAi therapeutics.
Recent Developments
The global RNAi technology market size reached US$ 2.75 Billion in 2024 from US$ 2.51 Billion in 2023 and is expected to reach US$ 6.63 Billion by 2033, growing at a CAGR of 10.4% during the forecast period 2025-2033. The market is expanding rapidly, driven by the clinical success of approved siRNA drugs, advances in delivery systems like GalNAc conjugates and lipid nanoparticles, and rising investments from pharma and biotech partnerships. North America currently dominates revenues, but Asia-Pacific is poised for the fastest growth due to increasing R&D and manufacturing capacity. The market outlook is strong, particularly in rare diseases, oncology, and metabolic disorders, though challenges in extra-hepatic delivery and high development costs remain key hurdles.
Key Market Trends & Insights
- The RNAi market is experiencing robust expansion, underpinned by the successful commercialization of multiple siRNA-based drugs and a growing number of late-stage clinical trials that continue to de-risk the modality. The approval of RNAi therapies for rare genetic and hepatic diseases has significantly increased confidence among regulators, investors, and pharmaceutical companies, creating a positive feedback loop for further R&D funding and partnership activity.
- RNAi is increasingly positioned within a crowded therapeutic ecosystem that includes antisense oligonucleotides (ASOs), CRISPR-based gene editing, and mRNA therapeutics. This competitive convergence is pushing RNAi companies to differentiate themselves through improved chemistry, extended durability of effect, and combination approaches. At the same time, intellectual property battles and overlapping innovation spaces underscore the importance of strategic alliances and clear positioning to secure long-term market share.
- North America dominates the RNAi technology market with the largest revenue share of 42.73% in 2024.
- The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 11.7% over the forecast period.
- Based on product type, the siRNA (small interfering RNA) segment led the market with the largest revenue share of 43.61% in 2024.
- The major market players in the RNAi technology market are Alnylam Pharmaceuticals, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Creative Biolabs, GenScript, Revvity, Promega Corporation, OriGene Technologies, Inc. and Altogen Biosystems, among others
- 2024 Market Size: US$ 2.75 Billion
- 2033 Projected Market Size: US$ 6.63 Billion
- CAGR (2025–2033): 10.4%
- North America: Largest market in 2024
- Asia Pacific: Fastest-growing market
Drivers-Proven clinical validation with first-to-market RNAi therapeutics is significantly driving the RNAi technology market growth
The proven clinical validation of first-to-market RNAi therapeutics is one of the most powerful catalysts driving the RNAi technology market’s growth. For years, RNAi was viewed largely as a promising research tool, but skepticism persisted around its clinical viability due to delivery and safety challenges. This changed with the approval of Onpattro (patisiran) in 2018, the first siRNA-based drug approved for treating hereditary transthyretin-mediated amyloidosis. Its success not only validated RNAi’s therapeutic potential but also demonstrated that gene silencing could translate into meaningful patient outcomes.
This milestone was quickly followed by other approvals, such as Givlaari (givosiran) for acute hepatic porphyria, Oxlumo (lumasiran) for primary hyperoxaluria, and Leqvio (inclisiran) for hypercholesterolemia, collectively establishing RNAi as a credible therapeutic modality. Each approval has progressively built trust among regulators, investors, and pharmaceutical companies, reducing uncertainties around safety, durability, and regulatory pathways.
These successes have proven RNAi’s scalability beyond ultra-rare diseases, with inclisiran marking a significant step into the large cardiovascular market. The commercial performance of these drugs, combined with positive Phase III trial results from emerging candidates, has attracted major partnerships and licensing deals between RNAi-focused biotechs like Alnylam and Arrowhead and global pharma leaders. This validation loop successful approvals driving partnerships, funding, and expanded pipelines, is significantly accelerating the overall RNAi market, transforming it from a niche innovation into a mainstream therapeutic platform.
Restraints-Regulatory complexity and evolving safety concerns are hampering the growth of the RNAi technology market
The growth of the RNAi technology market is hampered by ongoing regulatory complexity and evolving safety concerns, which create hurdles for both developers and investors. Despite several successful approvals, regulatory agencies like the FDA and EMA continue to scrutinize RNAi drugs closely due to risks such as off-target gene silencing, immune activation, and hepatotoxicity. Since RNAi therapies often involve repeat dosing for chronic diseases, regulators demand long-term safety data, which prolongs clinical timelines and increases costs. Manufacturing complexities, particularly in ensuring consistent quality of chemically modified oligonucleotides, add another layer of regulatory oversight.
Moreover, uncertainties remain around how RNAi therapies will be evaluated against competing modalities like CRISPR or antisense oligonucleotides, leading to inconsistencies in trial design expectations. These regulatory bottlenecks, combined with the lingering perception of RNAi as a “new” modality, slow down approvals and can dampen investor confidence when unexpected safety issues arise in clinical trials. As a result, while regulatory acceptance of RNAi has improved, the high bar for safety and evolving guidelines remain significant restraints to faster market growth.
Market Segment Analysis
The RNAi technology market is segmented based on product type, therapeutic application, end-user, and region.
Product Type-The siRNA (small interfering RNA) segment is dominating the RNAi technology market with a 43.61% share in 2024
The siRNA (small interfering RNA) segment is dominating the RNAi technology market because it has delivered the most successful and clinically validated products to date, establishing itself as the core therapeutic modality in RNAi. siRNAs are synthetic double-stranded oligonucleotides that precisely silence disease-causing genes, and their design flexibility, combined with advances in delivery technologies such as GalNAc conjugates and lipid nanoparticles, has made them commercially viable.
The landmark approval of Onpattro (patisiran) in 2018 for hereditary transthyretin-mediated amyloidosis was the first breakthrough, proving siRNA’s potential in rare genetic diseases. This was followed by other Alnylam products like Givlaari (givosiran) for acute hepatic porphyria, Oxlumo (lumasiran) for primary hyperoxaluria, and Amvuttra (vutrisiran), which further validated siRNA’s role in treating liver-related disorders. Additionally, Leqvio (inclisiran), co-developed by Novartis and Alnylam, marked a major expansion of siRNA into the cardiovascular market, addressing high cholesterol in a much larger patient population. These successes demonstrate siRNA’s scalability beyond ultra-rare diseases, making it the most commercially advanced RNAi segment.
Market Geographical Share
North America is expected to dominate the RNAi technology market with a 44.13% in 2024
North America holds dominance in the RNAi technology market due to its advanced biotech ecosystem, strong funding landscape, and early regulatory approvals of pioneering RNAi drugs. The US, in particular, is home to industry leaders such as Alnylam Pharmaceuticals, which has successfully commercialized multiple siRNA therapies, including Onpattro (patisiran), Givlaari (givosiran), and Oxlumo (lumasiran), setting global benchmarks for RNAi therapeutics. The region also spearheaded the launch of Leqvio (inclisiran) in collaboration with Novartis, marking a major expansion into the high-prevalence cardiovascular disease space.
North America benefits from supportive regulatory frameworks, with the FDA granting designations like orphan drug and breakthrough therapy that have accelerated development timelines for RNAi assets. Additionally, strong academic institutions and research centers in the US and Canada drive innovation in RNAi delivery systems and preclinical research. The presence of established pharmaceutical companies actively partnering with RNAi-focused biotechs further strengthens commercialization pathways. These factors, combined with a high prevalence of genetic and metabolic disorders, robust reimbursement infrastructure, and significant venture capital interest, ensure that North America continues to lead in both revenue share and pipeline advancement in the RNAi technology market.
Market Companies and Competitive Landscape
Top companies in the RNAi technology market include Alnylam Pharmaceuticals, Inc., Thermo Fisher Scientific Inc., Merck KGaA, Creative Biolabs, GenScript, Revvity, Promega Corporation, OriGene Technologies, Inc. and Altogen Biosystems, among others.
Alnylam Pharmaceuticals, Inc.: Alnylam Pharmaceuticals, Inc. is the undisputed leader in the RNAi technology market, having pioneered the first FDA-approved siRNA drug, Onpattro (patisiran), and subsequently expanding its portfolio with Givlaari, Oxlumo, and Amvuttra. The company has established a stronghold in rare genetic and hepatic disorders while also expanding into broader areas like cardiovascular disease through partnerships, such as with Novartis for Leqvio (inclisiran). With a robust pipeline, proprietary delivery platforms, and strategic collaborations, Alnylam continues to set industry benchmarks, driving both innovation and commercialization in RNAi therapeutics.
Recent Developments
- In March 2025, Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, highlighted the significance of the US Food and Drug Administration’s (FDA) approval of Qfitlia (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, to promote thrombin generation to rebalance hemostasis and prevent bleeds. Qfitlia is indicated in the U.S. for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B, with or without factor VIII or IX inhibitors (neutralizing antibodies).
- In March 2025, Alnylam Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Therapeutic Application
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Proven Clinical Validation with First-to-market RNAi Therapeutics
3.1.1.2. Advancements in Delivery Systems Enabling Expanded Indications
3.1.2. Restraints
3.1.2.1. Regulatory Complexity and Evolving Safety Concerns
3.1.2.2. Market Concentration in a Few Therapeutic Niches
3.1.3. Opportunity
3.1.3.1. Expansion into Extra-hepatic Diseases Through Next-gen Delivery Platforms
3.1.3.2. Targeting High-burden Chronic Conditions
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. RNAI TECHNOLOGY MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. siRNA (small interfering RNA) *
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. miRNA (microRNA)
5.4. RNAi Reagents & Kits
5.5. Others
6. RNAI TECHNOLOGY MARKET, BY THERAPEUTIC APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
6.1.2. Market Attractiveness Index, By Therapeutic Application
6.2. Rare Genetic Disorders*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Oncology
6.4. Cardiovascular & Metabolic Disorders
6.5. Neurological or Neurodegenerative Disorders
6.6. Infectious Diseases
6.7. Others
7. RNAI TECHNOLOGY MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Pharmaceutical & Biotech Companies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Academic & Research Institutes
7.4. Contract Research Organizations (CROs) & CDMOs
7.5. Others
8. RNAI TECHNOLOGY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Alnylam Pharmaceuticals, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Thermo Fisher Scientific Inc.
10.3. Merck KGaA
10.4. Creative Biolabs
10.5. GenScript
10.6. Revvity
10.7. Promega Corporation
10.8. OriGene Technologies, Inc.
10.9. Altogen Biosystems (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Therapeutic Application
2.5. Snippet by End-User
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Proven Clinical Validation with First-to-market RNAi Therapeutics
3.1.1.2. Advancements in Delivery Systems Enabling Expanded Indications
3.1.2. Restraints
3.1.2.1. Regulatory Complexity and Evolving Safety Concerns
3.1.2.2. Market Concentration in a Few Therapeutic Niches
3.1.3. Opportunity
3.1.3.1. Expansion into Extra-hepatic Diseases Through Next-gen Delivery Platforms
3.1.3.2. Targeting High-burden Chronic Conditions
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. RNAI TECHNOLOGY MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. siRNA (small interfering RNA) *
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. miRNA (microRNA)
5.4. RNAi Reagents & Kits
5.5. Others
6. RNAI TECHNOLOGY MARKET, BY THERAPEUTIC APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
6.1.2. Market Attractiveness Index, By Therapeutic Application
6.2. Rare Genetic Disorders*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Oncology
6.4. Cardiovascular & Metabolic Disorders
6.5. Neurological or Neurodegenerative Disorders
6.6. Infectious Diseases
6.7. Others
7. RNAI TECHNOLOGY MARKET, BY END-USER
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Pharmaceutical & Biotech Companies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Academic & Research Institutes
7.4. Contract Research Organizations (CROs) & CDMOs
7.5. Others
8. RNAI TECHNOLOGY MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.5. South America
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. Brazil
8.5.6.2. Argentina
8.5.6.3. Rest of South America
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Alnylam Pharmaceuticals, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Thermo Fisher Scientific Inc.
10.3. Merck KGaA
10.4. Creative Biolabs
10.5. GenScript
10.6. Revvity
10.7. Promega Corporation
10.8. OriGene Technologies, Inc.
10.9. Altogen Biosystems (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global RNAi Technology Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global RNAi Technology Market Value, By Therapeutic Application, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global RNAi Technology Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global RNAi Technology Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global RNAi Technology Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 7 Global RNAi Technology Market Value, By Therapeutic Application, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 9 Global RNAi Technology Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 11 Global RNAi Technology Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global RNAi Technology Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 14 North America RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 15 North America RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 16 North America RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 18 Europe RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 19 Europe RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Europe RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 26 South America RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 27 South America RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 South America RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Alnylam Pharmaceuticals, Inc.: Overview
Table 34 Alnylam Pharmaceuticals, Inc.: Product Portfolio
Table 35 Alnylam Pharmaceuticals, Inc.: Key Developments
Table 36 Thermo Fisher Scientific Inc.: Overview
Table 37 Thermo Fisher Scientific Inc.: Product Portfolio
Table 38 Thermo Fisher Scientific Inc.: Key Developments
Table 39 Merck KGaA: Overview
Table 40 Merck KGaA: Product Portfolio
Table 41 Merck KGaA: Key Developments
Table 42 Creative Biolabs: Overview
Table 43 Creative Biolabs: Product Portfolio
Table 44 Creative Biolabs: Key Developments
Table 45 GenScript: Overview
Table 46 GenScript: Product Portfolio
Table 47 GenScript: Key Developments
Table 48 Revvity: Overview
Table 49 Revvity: Product Portfolio
Table 50 Revvity: Key Developments
Table 51 Promega Corporation: Overview
Table 52 Promega Corporation: Product Portfolio
Table 53 Promega Corporation: Key Developments
Table 54 OriGene Technologies, Inc.: Overview
Table 55 OriGene Technologies, Inc.: Product Portfolio
Table 56 OriGene Technologies, Inc.: Key Developments
Table 57 Altogen Biosystems: Overview
Table 58 Altogen Biosystems: Product Portfolio
Table 59 Altogen Biosystems: Key Developments
Table 1 Global RNAi Technology Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global RNAi Technology Market Value, By Therapeutic Application, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global RNAi Technology Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global RNAi Technology Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global RNAi Technology Market Value, By Product Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 7 Global RNAi Technology Market Value, By Therapeutic Application, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 9 Global RNAi Technology Market Value, By End-User, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 11 Global RNAi Technology Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global RNAi Technology Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 14 North America RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 15 North America RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 16 North America RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 18 Europe RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 19 Europe RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 20 Europe RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 26 South America RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 27 South America RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 28 South America RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa RNAi Technology Market Value, By Product Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa RNAi Technology Market Value, By Therapeutic Application, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa RNAi Technology Market Value, By End-User, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa RNAi Technology Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Alnylam Pharmaceuticals, Inc.: Overview
Table 34 Alnylam Pharmaceuticals, Inc.: Product Portfolio
Table 35 Alnylam Pharmaceuticals, Inc.: Key Developments
Table 36 Thermo Fisher Scientific Inc.: Overview
Table 37 Thermo Fisher Scientific Inc.: Product Portfolio
Table 38 Thermo Fisher Scientific Inc.: Key Developments
Table 39 Merck KGaA: Overview
Table 40 Merck KGaA: Product Portfolio
Table 41 Merck KGaA: Key Developments
Table 42 Creative Biolabs: Overview
Table 43 Creative Biolabs: Product Portfolio
Table 44 Creative Biolabs: Key Developments
Table 45 GenScript: Overview
Table 46 GenScript: Product Portfolio
Table 47 GenScript: Key Developments
Table 48 Revvity: Overview
Table 49 Revvity: Product Portfolio
Table 50 Revvity: Key Developments
Table 51 Promega Corporation: Overview
Table 52 Promega Corporation: Product Portfolio
Table 53 Promega Corporation: Key Developments
Table 54 OriGene Technologies, Inc.: Overview
Table 55 OriGene Technologies, Inc.: Product Portfolio
Table 56 OriGene Technologies, Inc.: Key Developments
Table 57 Altogen Biosystems: Overview
Table 58 Altogen Biosystems: Product Portfolio
Table 59 Altogen Biosystems: Key Developments
LIST OF FIGURES
Figure 1 Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 2 Global RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 4 Global RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 5 Global RNAi Technology Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global RNAi Technology Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 7 siRNA (small interfering RNA) RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 8 miRNA (microRNA) RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 9 RNAi Reagents & Kits RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 10 Others RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 11 Global RNAi Technology Market Y-o-Y Growth, By Therapeutic Application, 2023-2033 (%)
Figure 12 Rare Genetic Disorders Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 13 Oncology Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 14 Cardiovascular & Metabolic Disorders Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 15 Neurological or Neurodegenerative Disorders Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 16 Infectious Diseases Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 17 Others Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 18 Global RNAi Technology Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 19 Pharmaceutical & Biotech Companies End-User in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 20 Academic & Research Institutes End-User in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 21 Contract Research Organizations (CROs) & CDMOs End-User in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 22 Others End-User in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 23 Global RNAi Technology Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 24 North America RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 25 North America RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 26 North America RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 27 North America RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 28 North America RNAi Technology Market Share, By Country, 2024 & 2033 (%)
Figure 29 Europe RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 30 Europe RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 31 Europe RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 32 Europe RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 33 Europe RNAi Technology Market Share, By Country, 2024 & 2033 (%)
Figure 34 Asia-Pacific RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 35 Asia-Pacific RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 36 Asia-Pacific RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 37 Asia-Pacific RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Asia-Pacific RNAi Technology Market Share, By Country, 2024 & 2033 (%)
Figure 39 South America RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 40 South America RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 41 South America RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 42 South America RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 43 South America RNAi Technology Market Share, By Country, 2024 & 2033 (%)
Figure 44 Middle East and Africa RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 45 Middle East and Africa RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 46 Middle East and Africa RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 47 Middle East and Africa RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 48 Alnylam Pharmaceuticals, Inc.: Financials
Figure 49 Thermo Fisher Scientific Inc.: Financials
Figure 50 Merck KGaA: Financials
Figure 51 Creative Biolabs: Financials
Figure 52 GenScript: Financials
Figure 53 Revvity: Financials
Figure 54 Promega Corporation: Financials
Figure 55 OriGene Technologies, Inc.: Financials
Figure 56 Altogen Biosystems: Financials
Figure 1 Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 2 Global RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 3 Global RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 4 Global RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 5 Global RNAi Technology Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global RNAi Technology Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
Figure 7 siRNA (small interfering RNA) RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 8 miRNA (microRNA) RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 9 RNAi Reagents & Kits RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 10 Others RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 11 Global RNAi Technology Market Y-o-Y Growth, By Therapeutic Application, 2023-2033 (%)
Figure 12 Rare Genetic Disorders Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 13 Oncology Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 14 Cardiovascular & Metabolic Disorders Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 15 Neurological or Neurodegenerative Disorders Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 16 Infectious Diseases Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 17 Others Therapeutic Application in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 18 Global RNAi Technology Market Y-o-Y Growth, By End-User, 2023-2033 (%)
Figure 19 Pharmaceutical & Biotech Companies End-User in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 20 Academic & Research Institutes End-User in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 21 Contract Research Organizations (CROs) & CDMOs End-User in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 22 Others End-User in Global RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 23 Global RNAi Technology Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 24 North America RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 25 North America RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 26 North America RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 27 North America RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 28 North America RNAi Technology Market Share, By Country, 2024 & 2033 (%)
Figure 29 Europe RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 30 Europe RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 31 Europe RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 32 Europe RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 33 Europe RNAi Technology Market Share, By Country, 2024 & 2033 (%)
Figure 34 Asia-Pacific RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 35 Asia-Pacific RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 36 Asia-Pacific RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 37 Asia-Pacific RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 38 Asia-Pacific RNAi Technology Market Share, By Country, 2024 & 2033 (%)
Figure 39 South America RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 40 South America RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 41 South America RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 42 South America RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 43 South America RNAi Technology Market Share, By Country, 2024 & 2033 (%)
Figure 44 Middle East and Africa RNAi Technology Market Value, 2022-2033 (US$ Billion)
Figure 45 Middle East and Africa RNAi Technology Market Share, By Product Type, 2024 & 2033 (%)
Figure 46 Middle East and Africa RNAi Technology Market Share, By Therapeutic Application, 2024 & 2033 (%)
Figure 47 Middle East and Africa RNAi Technology Market Share, By End-User, 2024 & 2033 (%)
Figure 48 Alnylam Pharmaceuticals, Inc.: Financials
Figure 49 Thermo Fisher Scientific Inc.: Financials
Figure 50 Merck KGaA: Financials
Figure 51 Creative Biolabs: Financials
Figure 52 GenScript: Financials
Figure 53 Revvity: Financials
Figure 54 Promega Corporation: Financials
Figure 55 OriGene Technologies, Inc.: Financials
Figure 56 Altogen Biosystems: Financials
